Prescient Therapeutics Limited (ASX:PTX)

Prescient Therapeutics Income Statement

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Other Revenue	4.36	3.71	2.43	1.89	1.19
Revenue	4.36	3.71	2.43	1.89	1.19
Revenue Growth (YoY)	17.35%	52.89%	28.52%	59.37%	15.17%
Gross Profit	4.36	3.71	2.43	1.89	1.19
Selling, General & Admin	4.83	3.71	3.2	2.82	2.29
Research & Development	6.72	6.97	6.22	3.4	2.49
Operating Expenses	11.89	10.9	9.89	7.1	5.43
Operating Income	-7.54	-7.19	-7.46	-5.21	-4.24
Interest Expense	-	-	-	-0.01	-0.01
Interest & Investment Income	0.23	0.69	0.46	0.04	0.07
Currency Exchange Gain (Loss)	-0.01	-0.02	-0.01	0.06	-0.01
EBT Excluding Unusual Items	-7.32	-6.52	-7	-5.12	-4.2
Asset Writedown	-	-1.72	-	-	-
Other Unusual Items	-	-	-	-	0.05
Pretax Income	-7.32	-8.24	-7	-5.12	-4.15
Net Income	-7.32	-8.24	-7	-5.12	-4.15
Net Income to Common	-7.32	-8.24	-7	-5.12	-4.15
Shares Outstanding (Basic)	805	805	728	648	612
Shares Outstanding (Diluted)	805	805	728	648	612
Shares Change (YoY)	-	10.69%	12.31%	5.88%	55.18%
EPS (Basic)	-0.01	-0.01	-0.01	-0.01	-0.01
EPS (Diluted)	-0.01	-0.01	-0.01	-0.01	-0.01
Free Cash Flow	-7.24	-7.4	-6.19	-4.32	-3.97
Free Cash Flow Per Share	-0.01	-0.01	-0.01	-0.01	-0.01
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-172.98%	-193.58%	-307.14%	-275.75%	-357.80%
Profit Margin	-168.09%	-221.91%	-288.47%	-270.85%	-349.97%
Free Cash Flow Margin	-166.27%	-199.28%	-254.97%	-228.50%	-335.08%
EBITDA	-7.54	-7.19	-7.46	-5.21	-4.24
EBITDA Margin	-172.97%	-193.56%	-	-275.68%	-
D&A For EBITDA	0	0	0	0	0
EBIT	-7.54	-7.19	-7.46	-5.21	-4.24
EBIT Margin	-172.98%	-193.58%	-	-275.75%	-

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.